|
A treatment to promote skin wound healing
Treatment of wounds with TGM shows improved recovery compared to control group in a span of 10 days.
Invention Summary:
Helminths are potent modulators of immune function capable of stimulating an immune response that includes significant wound healing effector functions. Effective wound repair requires both the direct reconstruction...
Published: 7/26/2024
|
Inventor(s): William Gause, Fei Chen, Zhugong Liu, Pankaj Mishra
Keywords(s): Small molecules
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics
|
|
SARS-COV-2 papain-like protease inhibitors as antivirals
Novel compounds and their use as an inhibitor for SARS-CoV-2.
Invention Summary:
Two oral SARS-CoV-2 antivirals are available, molnupiravir and Paxlovid. However, the limited efficacy, drug-drug interaction, and drug resistance are main challenges facing these two drugs. Additional oral antivirals with novel mechanisms of actions are clearly needed....
Published: 8/20/2024
|
Inventor(s): Jun Wang, Edward Arnold, Francesc Ruiz Figueras, Prakash Jadhav, Bin Tan, Ahmadullah Ansari, Ashima Chopra
Keywords(s): Antiviral, Small molecules
Category(s): Technology Classifications > COVID-19, Technology Classifications > Infectious Disease, Technology Classifications > Therapeutics, Technology Classifications > Healthcare & Life Sciences
|
|
Use of Retinoids in Congenital Erythropoietic Porphyria
Invention Summary:
Congenital erythropoietic porphyria (CEP) is an unaddressed orphan disease caused by a rare genetic disorder leading to accumulation of uro/coproporphyrin-I (uro-I) in tissues due to inhibition of the enzyme uroporphyrinogen-III synthase. Clinical manifestations of CEP include bone fragility, severe photosensitivity, and photo-mutilation....
Published: 8/28/2024
|
Inventor(s): Bishr Omary, Jordan Shavit
Keywords(s): Small molecules
Category(s): Technology Classifications > Therapeutics, Technology Classifications > Healthcare & Life Sciences
|
|
Combined Opioidergic and Beta-Adrenergic Drugs for
Cancer and Immune Diseases
Figure 1. (Left) Combined, synergistic treatment with naltrexone (NTX), propranolol (PRO), and Anti-PD1 antibody shows decrease in tumor size, by volume. (Right) Combined treatment of NTX, DPDPE, and PRO similarly decreases tumor size compared to controls.
Invention Summary:
One of the major cancer therapy approaches that is being...
Published: 5/8/2024
|
Inventor(s): Dipak Sarkar
Keywords(s): Anti-cancer, Small molecules
Category(s): Technology Classifications > Cancer, Technology Classifications > Healthcare & Life Sciences
|
|
Novel Selective Anti-chlamydial Compounds and Use
ze: 12px;color: #4F81BD;line-height: 1;border-collapse: collapse; }
A set of photographs showing inhibition of C. trachomatis by acylpyrazoline (Using compound 4)
Invention Summary:
Chlamydia trachomatis is the most common sexually transmitted pathogenic bacterium worldwide. If left untreated...
Published: 1/31/2024
|
Inventor(s): Huizhou Fan, Jacques Roberge
Keywords(s): Small molecules
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics
|
|
Sigma-1 Receptor Antagonists – Non-Addictive Pain Management
Invention Summary:
The sigma 1 receptor (S1R), a molecular chaperone protein located in the endoplasmic reticulum and plasma membranes, plays important roles in various pathological disorders including pain. The potential commercial applications of novel S1R antagonists are twofold: 1) as stand-alone therapy for the treatment of chronic neuropathic...
Published: 5/1/2024
|
Inventor(s): William Welsh, Youyi Peng
Keywords(s): Antiviral, Neurological disorder & neuropathic pain, Small molecules
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics
|
|
Novel Inhibitors of Keap1-Nrf2 Protein-Protein Interaction
Novel Small Molecule Direct Inhibitors of Keap1-Nrf2 Protein-Protein Interaction
Invention Summary:
Nrf2 is a key transcription factor mediating anti-inflammatory and antioxidant responses in the body. Keap1 is a well-known repressor of Nrf2 that targets Nrf2 for its rapid proteasomal degradation. Dysfunctional Keap1-Nrf2 axis contributes to...
Published: 12/4/2024
|
Inventor(s): Longqin Hu, Dhulfiqar Abed
Keywords(s): Small molecules
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics
|
|
Small Molecule Inhibitors of MIF for Inflammatory Diseases
Small molecules targeting to the inflammatory cytokine MIF could be a treatment for various diseases
Invention Summary:
A wide range of diseases can be addressed by targeting inflammatory cytokines. Although there are monoclonal antibody drugs that target, e. g., Tumor Necrosis Factor (TNF), no orally administrable small molecule inhibitor...
Published: 12/4/2024
|
Inventor(s): Achyutharao Sidduri
Keywords(s): Autoimmune, Inflammation, Small molecules
Category(s): Technology Classifications > Healthcare & Life Sciences
|
|
Novel Zinc Metallochaperone (ZMC) Complexes for Treatment of p53-Mutated Cancers
A) Novel mechanism of action: a short exposure to ZMCs increases zinc levels in tumors enough to restore normal structure/function to mutant p53 which leads to p53 mediated cancer cell death. B) Novel formulation: Synthesizing ZMCs as a zinc-loaded complex (Zn-1) improves survival in a pancreatic cancer mouse model compared to the ZMC compound alone....
Published: 10/21/2024
|
Inventor(s): Spencer Kimball, Darren Carpizo, John Gilleran
Keywords(s): Anti-cancer, Small molecules
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics
|
|
Novel Zinc Metallochaperone (ZMC) Complexes for Treatment of p53-Mutated Cancers
A) Novel mechanism of action: a short exposure to ZMCs increases zinc levels in tumors enough to restore normal structure/function to mutant p53 which leads to p53 mediated cancer cell death. B) Novel formulation: Synthesizing ZMCs as a zinc-loaded complex (Zn-1) improves survival in a pancreatic cancer mouse model compared to the ZMC compound alone....
Published: 4/21/2024
|
Inventor(s): Spencer Kimball, Darren Carpizo, John Gilleran
Keywords(s): Anti-cancer, Small molecules
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics
|
